Correlation Between Telomir Pharmaceuticals, and Emergent Biosolutions

Can any of the company-specific risk be diversified away by investing in both Telomir Pharmaceuticals, and Emergent Biosolutions at the same time? Although using a correlation coefficient on its own may not help to predict future stock returns, this module helps to understand the diversifiable risk of combining Telomir Pharmaceuticals, and Emergent Biosolutions into the same portfolio, which is an essential part of the fundamental portfolio management process.

By analyzing existing cross correlation between Telomir Pharmaceuticals, Common and Emergent Biosolutions, you can compare the effects of market volatilities on Telomir Pharmaceuticals, and Emergent Biosolutions and check how they will diversify away market risk if combined in the same portfolio for a given time horizon. You can also utilize pair trading strategies of matching a long position in Telomir Pharmaceuticals, with a short position of Emergent Biosolutions. Check out your portfolio center. Please also check ongoing floating volatility patterns of Telomir Pharmaceuticals, and Emergent Biosolutions.

Diversification Opportunities for Telomir Pharmaceuticals, and Emergent Biosolutions

-0.7

Correlation Coefficient

Telomir Pharmaceuticals,  Emergent Biosolutions

Excellent diversification

The 3 months correlation between Telomir and Emergent is -0.7. Overlapping area represents the amount of risk that can be diversified away by holding Telomir Pharmaceuticals, Commo and Emergent Biosolutions in the same portfolio, assuming nothing else is changed. The correlation between historical prices or returns on Emergent Biosolutions and Telomir Pharmaceuticals, is a relative statistical measure of the degree to which these equity instruments tend to move together. The correlation coefficient measures the extent to which returns on Telomir Pharmaceuticals, Common are associated (or correlated) with Emergent Biosolutions. Values of the correlation coefficient range from -1 to +1, where. The correlation of zero (0) is possible when the price movement of Emergent Biosolutions has no effect on the direction of Telomir Pharmaceuticals, i.e., Telomir Pharmaceuticals, and Emergent Biosolutions go up and down completely randomly.

Pair Corralation between Telomir Pharmaceuticals, and Emergent Biosolutions

Given the investment horizon of 90 days Telomir Pharmaceuticals, Common is expected to generate 3.16 times more return on investment than Emergent Biosolutions. However, Telomir Pharmaceuticals, is 3.16 times more volatile than Emergent Biosolutions. It trades about 0.23 of its potential returns per unit of risk. Emergent Biosolutions is currently generating about 0.06 per unit of risk. If you would invest  331.00  in Telomir Pharmaceuticals, Common on September 19, 2024 and sell it today you would earn a total of  160.00  from holding Telomir Pharmaceuticals, Common or generate 48.34% return on investment over 90 days.

Time Period	3 Months [change]
Direction	Moves Against
Strength	Weak
Accuracy	100.0%
Values	Daily Returns

Telomir Pharmaceuticals, Commo  vs.  Emergent Biosolutions

Telomir Pharmaceuticals,

Risk-Adjusted Performance

0 of 100

Very Weak

Over the last 90 days Telomir Pharmaceuticals, Common has generated negative risk-adjusted returns adding no value to investors with long positions. In spite of uncertain performance in the last few months, the Stock's essential indicators remain very healthy which may send shares a bit higher in January 2025. The recent disarray may also be a sign of long period up-swing for the firm investors.

Emergent Biosolutions

Risk-Adjusted Performance

7 of 100

OK

Compared to the overall equity markets, risk-adjusted returns on investments in Emergent Biosolutions are ranked lower than 7 (%) of all global equities and portfolios over the last 90 days. In spite of comparatively uncertain fundamental drivers, Emergent Biosolutions unveiled solid returns over the last few months and may actually be approaching a breakup point.

Pair Trading with Telomir Pharmaceuticals, and Emergent Biosolutions

The main advantage of trading using opposite Telomir Pharmaceuticals, and Emergent Biosolutions positions is that it hedges away some unsystematic risk. Because of two separate transactions, even if Telomir Pharmaceuticals, position performs unexpectedly, Emergent Biosolutions can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Emergent Biosolutions will offset losses from the drop in Emergent Biosolutions' long position.

The idea behind Telomir Pharmaceuticals, Common and Emergent Biosolutions pairs trading is to make the combined position market-neutral, meaning the overall market's direction will not affect its win or loss (or potential downside or upside). This can be achieved by designing a pairs trade with two highly correlated stocks or equities that operate in a similar space or sector, making it possible to obtain profits through simple and relatively low-risk investment.

Check out your portfolio center.

Note that this page's information should be used as a complementary analysis to find the right mix of equity instruments to add to your existing portfolios or create a brand new portfolio. You can also try the Bonds Directory module to find actively traded corporate debentures issued by US companies.